Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function.
Effects of renal insufficiency on the pharmacokinetics of vinpocetine and its main metabolite, apovincaminic acid (AVA) were investigated in the present study. The elimination rate constant, half-life, clearance, area under the curve and volume of distribution were measured and compared with reported values for subjects with normal renal function. Previous investigations have shown that the elimination half life of vinpocetine was 2.54 +/- 0.48 hours and half-life of AVA was 3.66 +/- 1.56 hours in healthy volunteers after i.v. administration of 10 mg vinpocetine.
D000328:Adult; D000368:Aged; D005260:Female; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D014665:Vasodilator Agents / Q000378:metabolism*; D014748:Vinca Alkaloids / Q000378:metabolism*
D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C032858:apovincaminic acid; C013983:vinpocetine